Status:
TERMINATED
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects wi...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- TTreatment with diet/exercise or with not more than half maximal dose of oral anti-diabetic drugs alone for at least 2 months
- Diet/exercise treated subjects with HbA1c between 7.0% and 11%, inclusive
- OAD (oral anti-diabetic drug) treated subjects with HbA1c between 7.0% and 10%, inclusive
- Body Mass Index (BMI) less than or equal to 45 kg/m\^2
Exclusion
- Treatment with insulin for the last 3 months, except short-term treatment for intercurrent illness
- Treatment with any drug that could interfere with the glucose level (besides use of a single anti-diabetic compound)
- Any serious medical condition
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
746 Patients enrolled
Trial Details
Trial ID
NCT00294723
Start Date
February 1 2006
End Date
November 1 2008
Last Update
March 7 2017
Active Locations (117)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Concord, California, United States, 94520
2
Novo Nordisk Investigational Site
Escondido, California, United States, 92025
3
Novo Nordisk Investigational Site
Fullerton, California, United States, 92835
4
Novo Nordisk Investigational Site
Inglewood, California, United States, 90301